Status:
COMPLETED
Effect of Vitamin K in Critically Ill Patients
Lead Sponsor:
Region Skane
Conditions:
Coagulation Factor Deficiency
Coagulopathy, Consumption
Eligibility:
All Genders
18+ years
Brief Summary
Critically ill patients with spontaneously prolonged pro-thrombin time, where administration of intravenous administration of phytomenadione (vitamin K) has been ordered by the treating physician will...
Detailed Description
Vitamin K-deficiency is common in the peri-operative and intensive care setting. It is often seen in patients with prolonged prothrombin complex (PK-INR). A prolonged (PK-INR) is sometimes treated wit...
Eligibility Criteria
Inclusion
- Critically ill patients at the postoperative care unit or at the intensive care unit with a prothrombin complex (PK-INR) \> 1.2 during office hours who are ordered parenteral phytomenadione 10 mg will be eligible for inclusion
Exclusion
- Warfarin treatment
- Treatment with novel oral anticoagulants
- Hepatocellular carcinoma
- Liver resection within 6 months
- Known pre-existing coagulopathy
Key Trial Info
Start Date :
February 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 20 2020
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT03782025
Start Date
February 13 2019
End Date
March 20 2020
Last Update
March 18 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Intensive and perioperative care. Skåne University Hospital. Lund
Lund, Skåne County, Sweden, 22185
2
Skåne University Hospital
Lund, Skåne County, Sweden, 22185